Navigation Links
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA Patients Reported Job Loss When Treated With HUMIRA Combination Therapy Compared to Methotrexate Alone

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) is one of the most common causes of disability in the Western world. New data released today show that rheumatoid arthritis (RA) patients treated with Abbott's HUMIRA(R) (adalimumab) stayed working longer, had fewer absences and reported greater improvements in work performance.

Results from three studies were presented today at the European League Against Rheumatism (EULAR) annual congress in Barcelona. One groundbreaking study, PRevention Of Work Disability (PROWD), investigated the effect that HUMIRA therapy can have on the length of time RA patients remain at work. This was the first prospective, placebo-controlled, anti-tumor necrosis factor (TNF) study that investigated this effect. PROWD showed that significantly more patients taking methotrexate (MTX) alone reported job loss or imminent job loss after 56 weeks compared with those treated with a combination of HUMIRA and MTX.

A second study of patient-reported measures in paid workers and homemakers with early RA suggested that treatment with HUMIRA and MTX significantly improved their ability to perform their responsibilities at two years. A third study showed that RA patients treated with HUMIRA worked significantly longer compared with patients taking disease-modifying anti-rheumatic drugs (DMARDs).

"The data show that treatment with HUMIRA may allow patients to be more productive both at home and in the workplace," said Paul Emery, M.D., professor of rheumatology, Leeds University, UK.

Five million people worldwide -- mostly between the ages of 25 and 55 -- are currently living with RA, which most often affects the hands, feet and wrists. Typically, joint damage can occur within two years
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
4. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
5. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
6. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
Post Your Comments:
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram ... by 2016. The North America ... share while Europe claims approximately ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals ... today that its Board of Directors has elected Mr. Daniel ... who continues as Chief Executive Officer of Immune. Mr. ... since 2013. Immune,s new Chairman, Mr. Daniel ... of shareholders and to continue to support the strategic vision ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... live webcast on Tuesday, May 3, 2011 at 4:30 p.m. ... will provide a business and financial update and review first ... press release may be accessed from the Investors section of ...
... April 21, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... and teleconference with management to discuss first quarter 2011 financial ... Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 ... for the first quarter ended March 31, 2011 will be ...
Cached Medicine Technology:Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... acids help new moms fight depression, according to a new ... Journal. ,"Depression in new mothers is common ... percent of postpartum women. In some high-risk populations, the percentage ... percent. Since depression has devastating effects on both mother and ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... gay governor, James E. McGreevy appears to be knocking on ... in the news for the right reasons. He has ... ,Former Gov. James E. McGreevy, who was brought up ... religion on Sunday at St. Bartholomew's Church in New York. ...
... of IT students here have developed a device that can enable ... ,Called 'E-Netra', it costs Rs.2,000-3,000 and it reads texts through ... heard through earphones. ,Right now it can only ... in Braille script. ,The Agra College team that took ...
... the information furnished by Indira Gandhi National Open University ... Parliament/State legislature or deemed to be university can ... norms and guidelines laid down by the Distance Education ... meeting held on March 23, 2007 had resolved that ...
... from 105 countries met Friday to formally adopt a 24-page ... global warming after five days of heated debate to reaching ... at 3:30 a.m. Friday," said Carloa Traverso Saibante, information officer ... ,Once the IPCC report is formally adopted, it will ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: